Q1 Earnings Estimate for MDxHealth Issued By William Blair

MDxHealth SA (NASDAQ:MDXH) – Research analysts at William Blair issued their Q1 2026 earnings estimates for shares of MDxHealth in a research note issued to investors on Wednesday, February 26th. William Blair analyst A. Brackmann expects that the company will earn ($0.13) per share for the quarter. The consensus estimate for MDxHealth’s current full-year earnings is ($1.15) per share. William Blair also issued estimates for MDxHealth’s Q2 2026 earnings at ($0.10) EPS, Q3 2026 earnings at ($0.07) EPS and Q4 2026 earnings at ($0.05) EPS.

MDXH has been the topic of several other reports. Piper Sandler dropped their price objective on shares of MDxHealth from $8.00 to $6.00 and set an “overweight” rating on the stock in a research note on Thursday, November 7th. Lake Street Capital began coverage on shares of MDxHealth in a research note on Thursday, October 31st. They issued a “buy” rating and a $7.00 price objective on the stock.

MDxHealth Stock Up 1.6 %

MDXH stock opened at $1.86 on Friday. The company has a fifty day moving average price of $2.01 and a 200 day moving average price of $2.20. MDxHealth has a 12 month low of $1.55 and a 12 month high of $3.85. The company has a market cap of $87.96 million, a price-to-earnings ratio of -1.22 and a beta of 1.34. The company has a debt-to-equity ratio of 3.14, a current ratio of 1.54 and a quick ratio of 1.45.

MDxHealth (NASDAQ:MDXH) last released its quarterly earnings results on Wednesday, February 26th. The company reported ($0.14) EPS for the quarter, beating the consensus estimate of ($0.21) by $0.07. MDxHealth had a negative net margin of 49.52% and a negative return on equity of 1,077.84%. The firm had revenue of $24.74 million during the quarter, compared to the consensus estimate of $22.67 million.

Hedge Funds Weigh In On MDxHealth

Institutional investors have recently bought and sold shares of the company. Geode Capital Management LLC acquired a new position in MDxHealth in the 4th quarter valued at $25,000. Oppenheimer & Co. Inc. grew its stake in shares of MDxHealth by 100.0% during the 4th quarter. Oppenheimer & Co. Inc. now owns 20,000 shares of the company’s stock worth $47,000 after purchasing an additional 10,000 shares during the period. FAS Wealth Partners Inc. grew its stake in shares of MDxHealth by 49.6% during the 4th quarter. FAS Wealth Partners Inc. now owns 24,425 shares of the company’s stock worth $58,000 after purchasing an additional 8,100 shares during the period. XTX Topco Ltd acquired a new position in shares of MDxHealth during the 4th quarter worth $63,000. Finally, Delta Investment Management LLC acquired a new position in shares of MDxHealth during the 4th quarter worth $81,000.

MDxHealth Company Profile

MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, Europe, and internationally. Its testing solutions includes Select mdx, a non-invasive urine test for prostate cancer that measures the expression of two mRNA cancer-related biomarkers; Confirm mdx for prostate cancer tissue test that validates epigenetic test that guides the detection of occult prostate cancer on a patient's previously biopsied negative tissue; and Resolved mdx for urinary tract infection that identifies personalized effective antibiotic options against the patient's infection.